4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-25-000017
CHIEF EXECUTIVE OFFICER sold 10,857 shares at an average $143.89 ($1,562,185)
- CHIEF EXECUTIVE OFFICER acquired 18,750 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Option exercise | +18,750 | 25,094 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −369 | $138.93 | $51,265 | 24,725 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −1,031 | $140.08 | $144,425 | 23,694 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −2,679 | $141.20 | $378,287 | 21,015 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −604 | $142.12 | $85,840 | 20,411 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −940 | $144.27 | $135,617 | 19,471 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −1,628 | $145.36 | $236,640 | 17,843 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −1,970 | $146.93 | $289,449 | 15,873 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −932 | $148.55 | $138,448 | 14,941 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −274 | $149.20 | $40,880 | 14,667 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −74 | $150.75 | $11,156 | 14,593 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Sale | −356 | $140.95 | $50,178 | 14,237 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2025-12-16 | Option exercise · Restricted Stock Unit | −18,750 | 93,750 | D | ||
| Open-market sales · 10,857 sh · avg $143.89 · $1,562,185 | |||||||
Loading xslF345X05/form4-12182025_101249.xml…